The drug portfolio under Ahmed A. H. Abdellatif includes several investigational anticancer agents in various stages of clinical development. Notable trials include studies on lorigerlimab, naporafenib, and eFT226, targeting prostate cancer, melanoma, and solid tumors. Despite no FDA-approved drugs, the pipeline shows promise with multiple recruiting and active trials.